Article Abstract

Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform

Authors: Clara Mayo de las Casas, Mónica Garzón-Ibañez, Núria Jordana-Ariza, Santiago Viteri-Ramírez, Irene Moya-Horno, Niki Karachaliou, Zaira Yeste, Raquel Campos, Sergi Villatoro, Ariadna Balada-Bel, Beatriz García-Peláez, Noemí Reguart, Cristina Teixidó, Eloisa Jantús, Silvia Calabuig, Cristina Aguado, Ana Giménez-Capitán, Ruth Román-Lladó, Ana Pérez-Rosado, Maria José Catalán, Jordi Bertrán-Alamillo, Silvia García-Román, Sonia Rodriguez, Lidia Alonso, Erika Aldeguer, Alejandro Martínez-Bueno, Maria González-Cao, Andrés Aguilar Hernandez, Juan Garcia-Mosquera, Maria de los Llanos Gil, Manuel Fernandez, Rafael Rosell, Miguel Ángel Molina-Vila

Abstract

Background: In a significant percentage of advanced non-small cell lung cancer (NSCLC) patients, tumor tissue is unavailable or insufficient for genetic analyses at time to progression. We prospectively analyzed the appearance of genetic alterations associated with resistance in liquid biopsies of advanced NSCLC patients progressing to targeted therapies using the NGS platform.
Methods: A total of 24 NSCLC patients were included in the study, 22 progressing to tyrosine kinase inhibitors and two to other treatments. Liquid biopsies samples were obtained and analyzed using the GeneReadTM QIAact Lung DNA UMI Panel, designed to enrich specific target regions and containing 550 variant positions in 19 selected genes frequently altered in lung cancer tumors. Previously, a retrospective validation of the panel was performed in clinical samples.
Results: Of the 21 patients progressing to tyrosine kinase inhibitors with valid results in liquid biopsy, NGS analysis identified a potential mechanism of resistance in 12 (57%). The most common were acquired mutations in ALK and EGFR, which appeared in 8/21 patients (38%), followed by amplifications in 5/21 patients (24%), and KRAS mutations in one patient (5%). Loss of the p.T790M was also identified in two patients progressing to osimertinib. Three of the 21 (14%) patients presented two or more concomitant alterations associated with resistance. Finally, an EGFR amplification was found in the only patient progressing to immunotherapy included in the study.
Conclusions: NGS analysis in liquid biopsies of patients progressing to targeted therapies using the GeneReader platform is feasible and can help the oncologist to make treatment decisions.

Article Options

Download Citation